Holen Sie sich die Stockscreener-App
155.01
0.72%
-1.13
Handel nachbörslich:
154.00
-1.01
-0.65%
Schlusskurs vom Vortag:
$156.14
Offen:
$156.11
24-Stunden-Volumen:
1.83M
Relative Volume:
1.02
Marktkapitalisierung:
$294.63B
Einnahmen:
$54.66B
Nettoeinkommen (Verlust:
$13.58B
KGV:
22.09
EPS:
7.0171
Netto-Cashflow:
$16.05B
1W Leistung:
+0.81%
1M Leistung:
+1.23%
6M Leistung:
+5.35%
1J Leistung:
+31.97%
1-Tages-Spanne:
$154.44
$156.38
1-Wochen-Bereich:
$149.33
$159.30
52-Wochen-Spanne:
$112.34
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
155.01 | 296.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,196.04 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 624.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 453.92B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 322.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Argus | Hold → Buy |
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2026-01-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-09-12 | Herabstufung | Goldman | Neutral → Sell |
| 2025-08-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Herabstufung | UBS | Buy → Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-05 | Hochstufung | Stifel | Hold → Buy |
| 2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
| 2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2021-03-10 | Herabstufung | Argus | Buy → Hold |
| 2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Bestätigt | Leerink Partners | Outperform |
| 2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Novartis stock trades steady as Q1 2026 revenue grows and Cosentyx expansion supports outlook - AD HOC NEWS
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline - Sahm
Novartis stock trades steady as Q2 2026 results highlight solid specialty medicines growth - AD HOC NEWS
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers Unveiled - TradingKey
Novartis second quarter sales rise 3% to $14.4 billion - grafa.com
Earnings call transcript: Novartis tops Q2 2026 forecasts as shares rise - Investing.com
Novartis ADR earnings beat by $0.23, revenue topped estimates - Investing.com
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US - Sahm
NVS Stock Quote Price and Forecast - CNN
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Sahm
Novartis stock holds steady as pipeline and global reach underpin long-term growth - AD HOC NEWS
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis highlights drug pipeline strength as global healthcare demand grows - AD HOC NEWS
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Sahm
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - Barchart.com
Why Does Novartis AG-Sponsored ADR (NYSE:NVS) Track the NYSE Composite? - Kalkine Media
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout - ChartMill
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition - sharewise.com
Novartis to acquire Myricx Bio for $1.5 billion - grafa.com
10 Newly Overvalued Stocks this Week - Morningstar
What's Going on with Vera Therapeutics Stock on Monday? - Sahm
NVSNovartis AG ADR Options - Finviz
NOTA Forecast — Price Target — Prediction for 2027 - TradingView
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States - Sahm
Novartis outlines growth path as pipeline and US exposure support long-term story - ad-hoc-news.de
Novartis stock holds steady after EAACI Rhapsido update. US trading stays in view. - Ad Hoc News
Novartis consensus picture on SIX, analysts keep a neutral view on the stock - AD HOC NEWS
Novartis opens the week with a cautious sector backdrop, shares in focus alongside Roche - AD HOC NEWS
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVS) - TradingView
Price to earnings forward of Novartis AG Sponsored ADR – MUN:NOTA - TradingView
Novartis oncology partnership with Antares, shares trade near analyst targets - AD HOC NEWS
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSC) - TradingView
Novartis focuses on oncology pipeline, shares track SMI pharma peers - ad-hoc-news.de
907122 Forecast — Price Target — Prediction for 2027 - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSD) - TradingView
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR Actuals & Estimates (BMFBOVESPA:N1VS34) - TradingView
NVS/N Forecast — Price Target — Prediction for 2027 - TradingView
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Sahm
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Novartis highlights pipeline progress, shares trade steadily on NYSE - Ad-hoc-news.de
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):